You can buy Tramedx at the lowest price in the online pharmacy Nextgen.ooo . Trametinib is a kinase inhibitor used to treat patients with certain types of melanoma, non-small cell lung cancer, and thyroid cancer.
 
The US Food and Drug Administration has approved the combined administration of dabrafenib and trametinib for the treatment of anaplastic thyroid cancer that cannot be removed with surgery or that has spread to other parts of the body (metastatic) and has a type of abnormal gene. , BRAF V600E (BRAF V600E mutation positive).
Trametinib is indicated as monotherapy for the treatment of patients with unresectable or metastatic melanoma who have not previously received BRAF inhibitor treatment and who have BRAF V600E or V600K mutations detected by an FDA-approved test.
 
It is used in combination with dabrafenib for:
Treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
Adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations detected by an FDA-approved test and node-positive disease after complete resection.
Treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation detected by an FDA-approved test.
Treatment of patients with locally advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation and no satisfactory locoregional treatment options.
 
Trametinib is a reversible allosteric inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 activation, as well as MEK1 and MEK2 kinase activity. MEK proteins are upstream regulators of extracellular signal-regulated kinase (ERK), which promotes cell proliferation. Trametinib is helpful in BRAF V600E or V600K melanoma because the mutation results in constitutive activation of the BRAF pathway, which includes MEK1 and MEK2.